NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.
暂无分享,去创建一个
Donald A Berry | D. Berry | A. Gown | S. Edge | S. Schnitt | R. Carlson | M. Hammond | A. Wolff | H. Burstein | D. Allred | L. Pierce | P. Ravdin | L. Goldstein | J. D. Iglehart | Robert W Carlson | Lori J Goldstein | D Craig Allred | Antonio C Wolff | Stuart J Schnitt | Harold J Burstein | Stephen B Edge | Lori J Pierce | Peter Ravdin | M Elizabeth Hammond | S. Moench | Allen Gown | James Dirk Iglehart | Susan Moench | Susan J. Moench
[1] Graham A. Colditz,et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study , 2011, Breast Cancer Research and Treatment.
[2] Seema A Khan,et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[3] R. Gelber,et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] Charles M. Perou,et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.
[5] Heinrich Sticht,et al. Estrogen and progesterone receptors: from molecular structures to clinical targets , 2009, Cellular and Molecular Life Sciences.
[6] C. Perou,et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] W. Han,et al. The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer. , 2009, American journal of surgery.
[8] G. Colditz,et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. , 2009 .
[9] S. Fox,et al. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. J. van de Vijver,et al. Estrogen receptor phenotypes defined by gene expression profiling. , 2009, Cancer treatment and research.
[11] S. Fuqua,et al. Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor α and its phosphorylation at serine 305 , 2009, Breast Cancer Research and Treatment.
[12] Laura Biganzoli,et al. Prognostic and predictive factors. , 2009, Cancer treatment and research.
[13] P. Fitzgibbons,et al. National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures. , 2009, Archives of pathology & laboratory medicine.
[14] D. Allred. The utility of conventional and molecular pathology in managing breast cancer , 2008, Breast Cancer Research.
[15] Clive R Taylor,et al. Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry , 2008, Applied immunohistochemistry & molecular morphology : AIMM.
[16] D. Allred. Commentary: hormone receptor testing in breast cancer: a distress signal from Canada. , 2008, The oncologist.
[17] Jingqin Luo,et al. Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.
[18] N. Habib,et al. The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer , 2008, Cancer.
[19] Gianluca Bontempi,et al. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.
[20] G. Colditz,et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer , 2008, Breast Cancer Research.
[21] M. Dieci,et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. , 2008, The oncologist.
[22] P. Lønning,et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? , 2008, The oncologist.
[23] K. Hede. Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. , 2008, Journal of the National Cancer Institute.
[24] M. Reymond,et al. Lost in Translation? A Systematic Database of Gene Expression in Breast Cancer , 2008, Pathobiology.
[25] M. Clemons,et al. Changes in breast tumour receptor status with time: A prospective study assessing the impact of obtaining confirmatory biopsy at metastatic recurrence on patient management , 2008 .
[26] G. Hortobagyi,et al. Prognostic impact of discordance/concordance of triple-receptor expression between primary tumor and metastasis in patients with metastatic breast cancer , 2008 .
[27] Edith A Perez,et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] D. Allred,et al. Problems and solutions in the evaluation of hormone receptors in breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Gown. Current issues in ER and HER2 testing by IHC in breast cancer , 2008, Modern Pathology.
[30] R. Gelber,et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Jack Cuzick,et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Charles M. Perou,et al. Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution , 2008, Clinical Cancer Research.
[33] Early Breast Cancer Trialists' Collaborative Group. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials , 2008, The Lancet.
[34] R. Peto,et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. , 2008, Lancet.
[35] I. Ellis,et al. Expression profiling technology: its contribution to our understanding of breast cancer , 2007, Histopathology.
[36] L. Goldstein,et al. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases , 2008, Breast Cancer Research and Treatment.
[37] E. Levin,et al. Estrogen receptors outside the nucleus in breast cancer , 2008, Breast Cancer Research and Treatment.
[38] B. O’Malley,et al. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] I. Nagtegaal,et al. Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays , 2007 .
[42] D. Allred,et al. Development of Standard Estrogen and Progesterone Receptor Immunohistochemical Assays for Selection of Patients for Antihormonal Therapy , 2007, Applied immunohistochemistry & molecular morphology : AIMM.
[43] P. Neven,et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] R. Sainson,et al. A Conserved Mechanism for Steroid Receptor Translocation to the Plasma Membrane* , 2007, Journal of Biological Chemistry.
[45] D. Rimm,et al. Quantitative analysis of estrogen receptor heterogeneity in breast cancer , 2007, Laboratory Investigation.
[46] R. Gelber,et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] David L Rimm,et al. Bimodal population or pathologist artifact? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] E. Perez,et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] R. Walker. Immunohistochemical markers as predictive tools for breast cancer , 2007, Journal of Clinical Pathology.
[50] C. Perou,et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. , 2007, Human pathology.
[51] I. Ellis,et al. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast , 2006, Journal of Clinical Pathology.
[52] D. Rimm,et al. Immunohistochemistry and quantitative analysis of protein expression. , 2009, Archives of pathology & laboratory medicine.
[53] M. Cronin,et al. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue , 2007, Breast Cancer Research and Treatment.
[54] M. Rossing,et al. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients , 2007, Breast Cancer Research.
[55] Karen A Gelmon,et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] F. Stossi,et al. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. , 2006, Molecular endocrinology.
[57] R M Levenson,et al. Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment II , 2006, Histopathology.
[58] D. Berry,et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. , 2006, JAMA.
[59] E. Levin,et al. Nature of functional estrogen receptors at the plasma membrane. , 2006, Molecular endocrinology.
[60] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] R. Pietras. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer. , 2006, The oncologist.
[62] A. Nobel,et al. The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.
[63] S. Schnitt. Estrogen receptor testing of breast cancer in current clinical practice: what's the question? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] Zhiyuan Hu,et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] C. Perou,et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.
[66] S. Bogen,et al. A molecular model of antigen retrieval using a peptide array. , 2006, American journal of clinical pathology.
[67] D. Rimm,et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. , 2005, Journal of the National Cancer Institute.
[68] A. Giordano,et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. , 2005, Endocrine-related cancer.
[69] C. Osborne,et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] J. Horiguchi,et al. Co-expressed type of ER and HER2 protein as a predictive factor in determining resistance to antiestrogen therapy in patients with ER-positive and HER2-positive breast cancer. , 2005, Oncology reports.
[71] C. Caldas,et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[73] D. Allred,et al. The Assessment of Hormone Receptors in Breast Cancer by Immunohistochemistry , 2005 .
[74] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[75] N. Sneige,et al. Estrogen Receptor Analysis for Breast Cancer: Current Issues and Keys to Increasing Testing Accuracy , 2005, Advances in anatomic pathology.
[76] A. Howell,et al. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes , 1996, Breast Cancer Research and Treatment.
[77] C. Gomez-Fernandez,et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. , 2005, American journal of clinical pathology.
[78] C. Geyer,et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma , 2005, Cancer.
[79] S. Schnitt,et al. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. , 2005, American journal of clinical pathology.
[80] A. Ramaioli,et al. Different clinical impact of estradiol receptor determination according to the analytical method: a study on 1940 breast cancer patients over a period of 16 consecutive years , 2005, Breast Cancer Research and Treatment.
[81] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[82] D. Allred,et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study , 2004, Modern Pathology.
[83] C. Osborne,et al. HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer , 2004, Clinical Cancer Research.
[84] J. Itoh,et al. Immunohistochemical Evaluation of Hormone Receptors in Breast Cancer: Which Scoring System Is Suitable for Highly Sensitive Procedures? , 2004, Applied immunohistochemistry & molecular morphology : AIMM.
[85] A. Gown,et al. Unmasking the mysteries of antigen or epitope retrieval and formalin fixation. , 2004, American journal of clinical pathology.
[86] P. Hall,et al. Prognostic and predictive factors. , 2004, Methods in molecular medicine.
[87] S. Hilsenbeck,et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer , 2004, Breast Cancer Research and Treatment.
[88] Anthony W. Norman,et al. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model , 2004, Nature Reviews Drug Discovery.
[89] Mårten Fernö,et al. Comparison of Immunohistochemical and Biochemical Assay of Steroid Receptors in Primary Breast Cancer Clinical Associations and Reasons for Discrepancies , 2003, Acta oncologica.
[90] N. Goldstein,et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. , 2003, American journal of clinical pathology.
[91] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[92] V. Jordan,et al. The estrogen receptor: a model for molecular medicine. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[93] C. Osborne,et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] L. Layfield,et al. Interlaboratory Variation in Results from Immunohistochemical Assessment of Estrogen Receptor Status , 2003, The breast journal.
[95] G. Figtree,et al. Truncated Estrogen Receptor &agr; 46-kDa Isoform in Human Endothelial Cells: Relationship to Acute Activation of Nitric Oxide Synthase , 2003, Circulation.
[96] P. Falb,et al. A Novel Quality Control Slide for Quantitative Immunohistochemistry Testing , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[97] P. Regitnig,et al. Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories , 2002, Virchows Archiv.
[98] D. DeMets,et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] C Blake Gilks,et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. , 2002, American journal of clinical pathology.
[100] S. Bogen,et al. Synthetic peptides identified from phage-displayed combinatorial libraries as immunodiagnostic assay surrogate quality-control targets. , 2002, Clinical chemistry.
[101] A. Douglas-Jones,et al. Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. , 2001, Journal of clinical pathology.
[102] Jian-ming Zheng,et al. Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression☆ ☆ This study was supported by the National Natural Science Foundation of China (No. 39870753) and Changhai Hospital ‘123’ Project. , 2001, Steroids.
[103] V. Speirs,et al. Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues , 2001, The Journal of Steroid Biochemistry and Molecular Biology.
[104] D. McDonnell,et al. The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators* , 2001, The Journal of Biological Chemistry.
[105] D B Evans,et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[106] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[107] M. Dowsett,et al. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. , 2001, Endocrine-related cancer.
[108] L. Bobrow,et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. , 2001, American journal of clinical pathology.
[109] D. Barnes,et al. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening , 2000, Journal of clinical pathology.
[110] B. Jasani,et al. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries , 2000, Journal of clinical pathology.
[111] S. Martino,et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study , 2000, International journal of cancer.
[112] D. Barnes,et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems , 2000, Journal of clinical pathology.
[113] K. Keyomarsi,et al. Expression of an estrogen receptor alpha variant protein in cell lines and tumors. , 2000, Molecular and cellular endocrinology.
[114] B. Katzenellenbogen,et al. Caveolin-1 Potentiates Estrogen Receptor α (ERα) Signaling , 1999, The Journal of Biological Chemistry.
[115] B. Katzenellenbogen,et al. Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha. , 1999, The Journal of biological chemistry.
[116] C K Osborne,et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] J. Riera,et al. Use of cultured cells as a control for quantitative immunocytochemical analysis of estrogen receptor in breast cancer. The Quicgel method. , 1999, American journal of clinical pathology.
[118] P B Sigler,et al. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[119] D. Allred,et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[120] J. Gustafsson,et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. , 1997, The Journal of clinical endocrinology and metabolism.
[121] Eva Enmark,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Human Estrogen Receptor �-Gene Structure, Chromosomal Localization, and Expression Pattern* , 2022 .
[122] J. Gustafsson,et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. , 1997, Endocrinology.
[123] D. Barnes,et al. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. , 1996, British Journal of Cancer.
[124] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[125] R. Gray,et al. Annual hazard rates of recurrence for breast cancer after primary therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[126] G. Greene,et al. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. , 1996, Gynecologic oncology.
[127] J. Gustafsson,et al. Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[128] B. Asselain,et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. , 1996, British Journal of Cancer.
[129] J. Graham,et al. Preferential Stimulation of Human Progesterone Receptor B Expression by Estrogen in T-47D Human Breast Cancer Cells (*) , 1995, The Journal of Biological Chemistry.
[130] D. Grignon,et al. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee. , 1995, Archives of pathology & laboratory medicine.
[131] M. Sliwkowski,et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. , 1995, Oncogene.
[132] H. Burke,et al. Criteria for prognostic factors and for an enhanced prognostic system , 1993, Cancer.
[133] D. Wilbur,et al. Estrogen and progesterone receptor detection in archival formalin-fixed, paraffin-embedded tissue from breast carcinoma: a comparison of immunohistochemistry with the dextran-coated charcoal assay. , 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[134] W. L. McGuire,et al. Breast cancer prognostic factors: evaluation guidelines. , 1991, Journal of the National Cancer Institute.
[135] P Chambon,et al. Two distinct estrogen‐regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. , 1990, The EMBO journal.
[136] C. Redmond,et al. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[137] K. Horwitz,et al. Multiple human progesterone receptor messenger ribonucleic acids and their autoregulation by progestin agonists and antagonists in breast cancer cells. , 1988, Molecular endocrinology.
[138] ADJUVANT TAMOXIFEN IN THE MANAGEMENT OF OPERABLE BREAST CANCER: THE SCOTTISH TRIAL Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh , 1987, The Lancet.
[139] D. Mutch,et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. , 1986, Cancer research.
[140] E B Cox,et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. , 1986, Cancer research.
[141] C. Redmond,et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[142] M. Press,et al. Structure and dynamics of the estrogen receptor. , 1986, Journal of steroid biochemistry.
[143] E B Cox,et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.
[144] Beahrs Oh,et al. The American Joint Committee on Cancer. , 1984 .
[145] S. Aamdal,et al. Estrogen receptors and long‐term prognosis in breast cancer , 1984, Cancer.
[146] O. Beahrs. The American Joint Committee on Cancer. , 1984, Bulletin of the American College of Surgeons.
[147] K. Horwitz,et al. In situ photolinked nuclear progesterone receptors of human breast cancer cells: subunit molecular weights after transformation and translocation. , 1983, Endocrinology.
[148] K. Seibert,et al. Hormone receptors in breast cancer , 1982 .
[149] A. Manni,et al. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy , 1980, Cancer.
[150] W. McGuire,et al. The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.
[151] M. Lippman,et al. Lack of estrogen receptor associated with an increased response rate to cytotoxic chemotherapy in metastatic breast cancer? , 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[152] R. Hähnel,et al. Prognostic value of estrogen receptors in primary breast cancer , 1979, Cancer.
[153] E. J. Gregory,et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. , 1977, Cancer research.
[154] W. McGuire. Estrogen receptors in human breast cancer. , 1973, The Journal of clinical investigation.
[155] C. D. HAAGENSEN,et al. Diseases of the Breast , 1972 .
[156] E. Jensen. On the Mechanism of Estrogen Action , 2015, Perspectives in biology and medicine.
[157] E. Rynearson. ENDOCRINE THERAPY , 1941 .